TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28254158

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 41
Study: 24636956

Group type: EXPERIMENTAL
Intervention: Fitted foot orthoses (FOs) with customised chair-side corrections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control foot orthoses made without corrections
Number of subjects: 60
Study: 22541719

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 25235

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 25235

Group type: EXPERIMENTAL
Intervention: Former smokers without COPD
Number of subjects: 25235

Group type: EXPERIMENTAL
Intervention: Former smokers who quit more than 10 years ago
Number of subjects: 25235

Group type: COMPARATOR
Intervention: Participants with COPD
Number of subjects: 25235
Study: 20420959

Group type: EXPERIMENTAL
Intervention: Abdominal draw-in manoeuvre in combination with ankle dorsiflexion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Abdominal draw-in manoeuvre alone
Number of subjects: 40
Study: 19045963

Group type: EXPERIMENTAL
Intervention: Coping-oriented couples therapy (COCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 60
Study: 15914517

Group type: EXPERIMENTAL
Intervention: Generic warfarin (Apo-warfarin)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Coumadin (control group)
Number of subjects: 7
Study: 12971525

Group type: EXPERIMENTAL
Intervention: HIV vaccine-related research protocols
Number of subjects: 1668
Study: 10489822

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8791228

Group type: EXPERIMENTAL
Intervention: Sweet pacifier
Number of subjects: 42

Group type: COMPARATOR
Intervention: Latex pacifier
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maternal heartbeat sounds
Number of subjects: 42
Study: 1346963

Group type: EXPERIMENTAL
Intervention: Inhaled beta 2-agonists (higher doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular use of inhaled beta 2-agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (additional therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel longer-acting inhaled beta 2-agonists (salmeterol and formoterol)
Number of subjects: 0
Study: 6497569

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg twice a day for two weeks)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 798
Study: 31115768

Group type: EXPERIMENTAL
Intervention: Proposed verification secure framework using CIA standard, blockchain, PSO, and AES techniques.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid model pattern combining RFID and finger vein biometrics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steganography technique based on proposed pattern model.
Number of subjects: 0
Study: 29488154

Group type: EXPERIMENTAL
Intervention: Fasiglifam (25 mg oral dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal hepatic function (control group)
Number of subjects: 30
Study: 26775036

Group type: EXPERIMENTAL
Intervention: Autonomy support present, implementation intention present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomy support present, implementation intention absent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomy support absent, implementation intention present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autonomy support absent, implementation intention absent
Number of subjects: 0
Study: 25584315

Group type: EXPERIMENTAL
Intervention: PRF gel (experimental group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PRF gel and PRF membrane (experimental group II)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement (control group)
Number of subjects: 15
Study: 22449332

Group type: EXPERIMENTAL
Intervention: Combination treatment with darbepoetin and G-CSF (n = 41), G-CSF was treated for 3 days at a dose of 10 μg/kg/day, plus a single intravenous injection of 4.5 μg/kg of darbepoetin after coronary angioplasty.
Number of subjects: 60

Group type: COMPARATOR
Intervention: G-CSF alone (n = 19), treated for 3 days at a dose of 10 μg/kg/day.
Number of subjects: 60
Study: 20807664

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg, twice-daily, 7 doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dalteparin (5000 IU, once-daily, 4 doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ximelagatran (24 mg, twice-daily, 7 doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study: 17289734

Group type: EXPERIMENTAL
Intervention: Education and reassurance
Number of subjects: 0
Study: 15800321

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)
Number of subjects: 172
Study: 12553109

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily for 28 days
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 92
Study: 9805324

Group type: EXPERIMENTAL
Intervention: Self-Ordered Pointing Task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring deficit interpretation
Number of subjects: 0
Study: 8594122

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine (277 ± 77 mg daily, given every 12 hr)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine
Number of subjects: 35
Study: 1706015

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 300 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diuretic (25 mg hydrochlorothiazide and 50 mg triamterene)
Number of subjects: 85
Study: 6785336

Group type: EXPERIMENTAL
Intervention: Long-term chrysotherapy (gold therapy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 14
Study: 30343408

Group type: EXPERIMENTAL
Intervention: Peer instruction (PI)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Self-explanation (SE)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Peer instruction (PI) and Self-explanation (SE)
Number of subjects: 317
Study: 29183324

Group type: EXPERIMENTAL
Intervention: Bar (565 kJ, 7.5 g EAAs, 40% L-leucine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gel (477 kJ, 7.5 g EAAs, 40% L-leucine)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 21
Study: 25671797

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with the Solitaire FR stent retriever
Number of subjects: 70

Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 70
Study: 24598293

Group type: EXPERIMENTAL
Intervention: Sini decoction (Chinese herb group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (corticoid group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 22175445

Group type: EXPERIMENTAL
Intervention: Collaborative behavioral management (CBM)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Standard parole (SP)
Number of subjects: 476
Study: 20875372

Group type: EXPERIMENTAL
Intervention: Orally dosed azithromycin
Number of subjects: 160
Study: 17032712

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mug twice a day
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Calcitriol + ET/HT
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: ET/HT
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 15784801

Group type: EXPERIMENTAL
Intervention: Trauma writing group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control writing group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 92
Study: 12208905

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone autograft
Number of subjects: 56

Group type: COMPARATOR
Intervention: Two-strand semitendinosus-gracilis autograft
Number of subjects: 56
Study: 9802132

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8589000

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 micrograms/kg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: GM‐CSF (5 micrograms/kg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 39

Group type: COMPARATOR
Intervention: GM‐CSF
Number of subjects: 39
Study: 2474480

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside monophosphate
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 766568

Group type: EXPERIMENTAL
Intervention: Non-dominant ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dominant ECT
Number of subjects: 0
Study: 31410778

Group type: EXPERIMENTAL
Intervention: Recumbent cycloergometer training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental hyperbaric oxygen therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (without intervention)
Number of subjects: 60
Study: 28482137

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 26112278

Group type: EXPERIMENTAL
Intervention: Milnacipran (open-label for 8 weeks, followed by double-blind randomization for 8 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milnacipran (open-label extension study up to 52 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (double-blind randomization for 8 weeks)
Number of subjects: 20
Study: 23111126

Group type: EXPERIMENTAL
Intervention: Manipulation of visual feedback conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of region of workspace
Number of subjects: 0
Study: 22779693

Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg QD
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg BID
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron (all doses)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 19827645

Group type: EXPERIMENTAL
Intervention: felodipin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study: 17209192

Group type: COMPARATOR
Intervention: Placebo (0 mg gluten)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 10 mg gluten
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 50 mg gluten
Number of subjects: 49
Study: 15313360

Group type: EXPERIMENTAL
Intervention: Oropharyngeal and nasopharyngeal suctioning before delivery of the shoulders (n=1263)
Number of subjects: 2514

Group type: COMPARATOR
Intervention: No suctioning before delivery (n=1251)
Number of subjects: 2514

Group type: EXPERIMENTAL
Intervention: Oropharyngeal and nasopharyngeal suctioning before delivery of the shoulders
Number of subjects: 2514

Group type: COMPARATOR
Intervention: No suctioning before delivery
Number of subjects: 2514
Study: 11677102

Group type: EXPERIMENTAL
Intervention: Individual support (IS) intervention including intensified primary healthcare
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 416
Study: 9389816

Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 109
Study: 8077329

Group type: EXPERIMENTAL
Intervention: LHRHa (deslorelin) administered sc at a dose of 4 micrograms/kg.day for a period of 4 yr
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3438117

Group type: EXPERIMENTAL
Intervention: General Discrimination Group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reading Discrimination Group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Study Skills Group
Number of subjects: 90
Study: 30553693

Group type: EXPERIMENTAL
Intervention: Personal financial incentive (10 Swiss Francs per month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Charity financial incentive (10 Swiss Francs per month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Charity financial incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steps per day and non-usage attrition
Number of subjects: 0
Study: 29378703

Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg twice daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ceftazidime 25 mg/kg every 8 hours (q8h)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ceftazidime 50 mg/kg every 8 hours (q8h)
Number of subjects: 51
Study: 27603346

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin with concurrent radiotherapy (SCCCR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cisplatin alone with concurrent radiotherapy (CCCR)
Number of subjects: 72
Study: 24922488

Group type: EXPERIMENTAL
Intervention: Combination of TAU and neurofeedback (n = 45)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 26)
Number of subjects: 71
Study: 22424708

Group type: EXPERIMENTAL
Intervention: Pyramidal flap design
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Envelope flap design
Number of subjects: 19

Group type: COMPARATOR
Intervention: Triangular flap design
Number of subjects: 19
Study: 20864729

Group type: EXPERIMENTAL
Intervention: Behavioral intervention adapted from Project Sugar 2, involving nurse and community health worker support for diabetes self-management.
Number of subjects: 0
Study: 18617079

Group type: COMPARATOR
Intervention: 2 weeks of nicotine patches
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: 8 weeks of nicotine patches
Number of subjects: 1154
Study: 16423095

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (6 sessions of 30 minutes each)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study: 12297208

Group type: EXPERIMENTAL
Intervention: Norsteroid supplementation (224 mg of 19‐nor‐4‐androstene‐3,17‐dione and 120 mg of 19‐nor‐4‐androstene‐3,17‐diol, total daily dose = 344 mg) for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 10
Study: 10336913

Group type: EXPERIMENTAL
Intervention: Anteroanterior electrode position
Number of subjects: 90

Group type: COMPARATOR
Intervention: Anteroposterior electrode position
Number of subjects: 90
Study: 7570331

Group type: EXPERIMENTAL
Intervention: Intravenous cefotaxime 2 gm
Number of subjects: 775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study: 2229793

Group type: EXPERIMENTAL
Intervention: Procainamide (12 to 15 mg/kg body weight)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Propafenone (1 to 2 mg/kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 55
Study: 7437173

Group type: EXPERIMENTAL
Intervention: Physical training programme
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 30649974

Group type: EXPERIMENTAL
Intervention: Serious game as a teaching tool
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual teaching without the serious game
Number of subjects: 46
Study: 28370947

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 6 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Health Education (HE) for 6 weeks
Number of subjects: 119
Study: 26098036

Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 620
Study: 24249359

Group type: EXPERIMENTAL
Intervention: Risk-reducing surgery (RRS)
Number of subjects: 691

Group type: COMPARATOR
Intervention: No risk-reducing surgery (no RRS)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Any form of RRS
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Both types of surgery (bilateral mastectomy and ovarian surgery)
Number of subjects: 691
Study: 21221045

Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System (in-the-mouth bone conduction device)
Number of subjects: 28
Study: 19725251

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg taken once daily for approximately 17 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17151592

Group type: EXPERIMENTAL
Intervention: Foods containing oat beta‐glucan
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 97
Study: 15126760

Group type: EXPERIMENTAL
Intervention: MRSA group
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study: 11343043

Group type: EXPERIMENTAL
Intervention: Iron supplements, 1 mg/kg/d from 4 to 9 months
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo from 4 to 6 months and iron from 6 to 9 months
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo from 4 to 9 months
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Iron supplements from 6 to 9 months
Number of subjects: 232
Study: 9625273

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) with oral diazepam (5 mg)
Number of subjects: 8
Study: 7824501

Group type: EXPERIMENTAL
Intervention: unspecific inhalatory provocation tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: percentile changes of function parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: survival time model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: best case/worst case analysis
Number of subjects: 0
Study: 2843130

Group type: EXPERIMENTAL
Intervention: GS + mitomycin C (MMC) 10 mg + adriamycin (ADR) 20 mg (group A, n = 45)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: GS + MMC 10 mg + ADR 20 mg + 200 mg/day of oral 5‐fluorouracil (5‐FU) (group B, n = 36)
Number of subjects: 112

Group type: COMPARATOR
Intervention: GS + 200 mg/day of 5‐FU (group C, n = 31)
Number of subjects: 112
Study: 29297260

Group type: EXPERIMENTAL
Intervention: MFGM (1 g/day) with light gymnastic exercise
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo with light gymnastic exercise
Number of subjects: 71
Study: 27207203

Group type: EXPERIMENTAL
Intervention: CPS putty alone (Group PUT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CPS putty and PRP (Group PRP)
Number of subjects: 20
Study: 24906581

Group type: EXPERIMENTAL
Intervention: Hatha Yoga Group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 51
Study: 22225628

Group type: EXPERIMENTAL
Intervention: Psychotherapy plus treatment as usual (P + TAU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 40
Study: 20358002

Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg t.i.d.)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Famotidine (20 mg b.i.d.)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 51
Study: 18331364

Group type: EXPERIMENTAL
Intervention: CD203c
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CD63
Number of subjects: 27
Study: 15130042

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) used for bonding 121 teeth
Number of subjects: 14

Group type: COMPARATOR
Intervention: Composite resin used for bonding 121 teeth
Number of subjects: 14
Study: 11548979

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 11
Study: 9661593

Group type: EXPERIMENTAL
Intervention: Bioavailable estrogen (E) levels
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Serum total testosterone (T) and estrogen (E) levels
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Urinary N-telopeptide of type I collagen (NTx) excretion
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Serum bioavailable T and E levels
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Serum bioavailable E level
Number of subjects: 650
Study: 8310510

Group type: EXPERIMENTAL
Intervention: rh‐SOD (200 mg intravenously during surgery)
Number of subjects: 0
Study: 3416710

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 159

Group type: COMPARATOR
Intervention: Other sulfonylureas
Number of subjects: 159

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 159
Study: 31606257

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol/organofunctional silane solution (IOS) treatment
Number of subjects: 600

Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 600
Study: 29542399

Group type: EXPERIMENTAL
Intervention: Psychotherapy provided by supervised nurses
Number of subjects: 10
Study: 28449212

Group type: EXPERIMENTAL
Intervention: Early ECV (34-36 weeks' gestation)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Delayed ECV (at or after 37 weeks)
Number of subjects: 1776
Study: 26241529

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 80
Study: 24441084

Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 64
Study: 21435252

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 21148

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 21148

Group type: EXPERIMENTAL
Intervention: Physical activity during leisure time (Men)
Number of subjects: 21148

Group type: EXPERIMENTAL
Intervention: Physical activity during leisure time (Women)
Number of subjects: 21148

Group type: EXPERIMENTAL
Intervention: Occupational physical activity (Women)
Number of subjects: 21148

Group type: EXPERIMENTAL
Intervention: Family history of myocardial infarction
Number of subjects: 21148
Study: 18429682

Group type: EXPERIMENTAL
Intervention: Percutaneous antegrade ureterolithotripsy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Retrograde ureterolithotripsy
Number of subjects: 91